人直肠癌相关抗原单克隆抗体特异性及其与预后的关系

目的　研究人直肠癌相关抗原单克隆抗体 (HM 93- 4McAb)的特异性 ,为生物导向诊断、治疗奠定基础。方法　应用 (HM93- 4McAb)与 85例人直肠癌标本进行间接免疫荧光技术检测。结果　 (1)DukesC期 (HM93- 4McAb)体阳性率 96 .2 %明显高于A期、B期 (47.6 % ,6 0 % ) ,与D期 88.8%比较无明显差异性。 (2 )中分化腺癌阳性率 10 0 %明显高于高分化腺癌及粘液癌 (P <0 .0 1)。 (3)直肠癌相关抗原的高表达与患者预后有明显的关系。结论　HM93- 4McAb可用于直肠癌的临床免疫病理分型诊断、药物标记生物导向诊断与治疗的载体。

Peculiarity of rectum carcinoma associated antigenic monoclonal an tibody in human and it's prognosis significance

Objective To research the peculiarity of rectum carcinoma associated antigenic monoclonal antibody (McAb) in human and offer a foundation for the guiding treatment and diagnosis of biology. Methods Indirective immune fluorescence technique was performed in 85 specimens of rectum carcinoma with rectum associated antigenic HM93-4 monoclonal antibody (HM93-4 McAb). Results (1)The positive rate (96.2%) in Dukes phase C was significantly higher than that in phase A(47.6%,10/21) and phase B (60%),and no significant differences between phase C and D (88.8%,16/18); (2)The positive rate in middle differentiation gland carcinoma 100%(35/35) was significantly higher than that in high differentiation gland carcinoma(P<0.01);(3) There was a obvious relation between the high express of rectum carcinoma associated antigen and patient’s prognosis; Conclusion HM93-4 McAb can be used as a carrier in guiding diagnosis and biologic treatment and a medicine maker for rectum gland carcinoma.